相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
P. J. Hesketh et al.
ANNALS OF ONCOLOGY (2014)
Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy
Shota Hamada et al.
SUPPORTIVE CARE IN CANCER (2014)
Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
H. Saito et al.
ANNALS OF ONCOLOGY (2013)
Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy
F. Longo et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens: A Hoosier Oncology Group Study
Costantine Albany et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy
Kenjiro Aogi et al.
SUPPORTIVE CARE IN CANCER (2012)
Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement
Lawrence H. Einhorn et al.
SUPPORTIVE CARE IN CANCER (2011)
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Ethan Basch et al.
JOURNAL OF ONCOLOGY PRACTICE (2011)
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
Lijun Tan et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer
Lawrence H. Einhorn et al.
SUPPORTIVE CARE IN CANCER (2007)
A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis
K. Jordan et al.
SUPPORTIVE CARE IN CANCER (2007)
Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting
Eyal Meiri et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy
J Vardy et al.
BRITISH JOURNAL OF CANCER (2006)
Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment
H. J. Schmoll et al.
ANNALS OF ONCOLOGY (2006)
Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? - Systematic re-evaluation of clinical evidence and drug cost implications
O Geling et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain
GJ Sanger
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in US and Japanese healthy subjects
R Stoltz et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group
PJ Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Effects of the neurolunin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone
JB McCrea et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting - Results from a randomized, double-blind, placebo-controlled trial in Latin America
S Poli-Bigelli et al.
CANCER (2003)
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists
PJ Hesketh et al.
EUROPEAN JOURNAL OF CANCER (2003)
Curing metastatic testicular cancer
LH Einhorn
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Central neurocircuitry associated with emesis
PJ Hornby
AMERICAN JOURNAL OF MEDICINE (2001)
The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours
AM Cook et al.
BRITISH JOURNAL OF CANCER (2001)
Potential of substance P antagonists as antiemetics
P Diemunsch et al.
DRUGS (2000)
Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs
JJ Hale et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
分享论文
